Clinical health outcomes, registries, and analytics
Be an early applicant
Clinical health outcomes, registries, and analytics
101-200 employees
Be an early applicant
101-200 employees
Unlocking the power of healthcare data to measure and predict outcomes, accelerate medical research, and improve clinical decision-making.
Jump to section
Unlocking the power of healthcare data to measure and predict outcomes, accelerate medical research, and improve clinical decision-making.
37% employee growth in 12 months
Medical data has traditionally been difficult to obtain. Yet access for health care providers could help to reduce some of the $1.6 trillion spent annually on healthcare costs for chronic conditions in the U.S. alone.
OM1 is a medical data service company offering real-time patient data for health professionals to review and utilize. This aggregated data assists with the early identification of illnesses and can be used as evidence in regulatory approvals. OM1 has launched a series of registries where medical professionals can share data and insights for specific conditions such as Multiple Sclerosis and Osteoarthritis.
Other companies attracting interest in this space include HealthVerity and Aetion, which supply databases used by pharmaceutical companies for drug research and development. OM1 sits apart from these providers in a middle-tier away from the large data centers but larger than providers focused on data from smaller research groups.
The company is focused on developing its platform, with a focus on adding datasets to help tackle Parkinson's disease and building out an AI-based product to provice personalised information about diagnosis, treatments and risks from a dataset composed of the records of over 300 million patients.
Freddie
Company Specialist at Welcome to the Jungle
Jul 2021
$85m
LATE VC
Dec 2019
$50m
SERIES C
This company has top investors
Richard Gliklich
(CEO)Richard qualified as a Physician at Harvard Medical School before working as CEO of Outcome and President of Quintiles for a combined 16 years. They work part time as a Professor at Harvard Medical School, alongside having founded OM1 in 2015.